EpCAMlow CTC have been found significantly associated with tumor depth, lymph node metastasis, and increased malignancy in gastric and endometrial cancers after staining by anti-CD45, anti-EpCAM, anti-CK, and anti-CEA (CD66e) antibodies [30, 31]. The gene discussed is EPCAM; the disease is metastatic malignant neoplasm in the lymph nodes.